GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo

Abnormallyactivated FGFR1 has been validated as a therapeutic target for differentcancers. Although a variety of FGFR inhibitors have shown benefit in manyclinical patients with FGFR1 aberration, FGFR1 mutant resistance such as V561Mmutation, has been reported. To date however, no FGFR inhibitors ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Kaili, Tang, Xia, Guo, Jing, He, Rui, Chan, Shingpan, Song, Xiaojuan, Tu, Zhengchao, Wang, Yuting, Ren, Xiaomei, Ding, Ke, Zhang, Zhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290231/
https://www.ncbi.nlm.nih.gov/pubmed/34114373
http://dx.doi.org/10.1002/cam4.4041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290231/
https://www.ncbi.nlm.nih.gov/pubmed/34114373
http://dx.doi.org/10.1002/cam4.4041

Ejemplares similares